SYMPTOMS

  • There is an average of 1-2 year delay from symptom onset to diagnosis1-3
  • The most common symptoms of IPF are dyspnea and dry cough4,5
  • Patients may present with digital clubbing6-8
  • Dry, inspiratory crackles are another common sign of IPF4,9

COMMON SYMPTOMS SIGNIFICANTLY IMPACT QUALITY OF LIFE IN PATIENTS WITH IPF.10

  • Depression: Patients may experience fear, worry, anxiety, and panic related to their poor prognosis10,11
  • Fatigue: Fatigue/exhaustion occurs frequently,10 and is exacerbated by further muscle deconditioning11
  • Dyspnea: Dyspnea is universal in patients with IPF11 and is extremely distressing10
  • Cough: Chronic cough causes significant impairment in patients’ lives10
  • Dyspnea and physical function capacity are strong drivers of health-related quality of life12

DIFFICULTY WITH DIAGNOSIS IS COMMON IN PATIENTS WITH IPF.1-3

  • Difficulty with diagnosis is common, as the early symptoms of IPF are nonspecific and the disease itself is rare.13,14
    • Symptoms may be attributed to more common ailments such as bronchitis, asthma, chronic obstructive pulmonary disease (COPD), emphysema, or heart disease14
  • 38% of patients report seeing 3 or more physicians before receiving a diagnosis of IPF14
  • >50% of patients are initially misdiagnosed14
  • 1-2 year delay between onset of symptoms and diagnosis1-3

THE DIAGNOSTIC PROCESS CAN TAKE AN AVERAGE OF 1-2 YEARS1-3

  • Bronchitis, asthma, COPD, emphysema, or heart disease are often considered first, as symptoms of IPF are common manifestations of these diseases14
  • Delayed referral to subspecialty care center was associated with higher mortality rates in patients with IPF. Delay is defined as time from onset of dyspnea to time of initial evaluation at a tertiary care center15

DIAGNOSTIC TOOLS

There are several diagnostic tools for evaluating interstitial lung disease.

CLINICAL ASSESSMENT

  • Comprehensive medical history4,16,17
    • Past medical history4,18
    • Current and past chronic medications4,18
    • Social history4,18
    • Family history4,18,19
    • IPF is a diagnosis of exclusion, making a complete history essential to identifying potential causes of dyspnea and cough4
  • Physical examination — Chest auscultation4
  • Pulmonary function testing:4,17 — FVC, forced expiratory volume in 1 second (FEV1), diffusing capacity of the lung for carbon monoxide (DLCO), lung volumes
    • IPF shows a restrictive defect20
  • 6-minute walk test (6MWT)4
  • Pulse oximetry21
  • Cardiac evaluation to rule out heart disease21
  • Serologic testing to exclude connective tissue disease (CTDs)4,16,22

RADIOLOGICAL ASSESSMENT

  • Chest x-ray18
  • HRCT4,16
  • Usual interstitial pneumonia pattern
    • Subpleural, basal predominance
    • Heterogeneous distribution
    • Honeycombing with/without traction bronchiectasis or bronchiolectasis

PROCEDURAL ASSESSMENT

  • Bronchoscopy
  • Surgical lung biopsy (if necessary)4,16

MULTIDISCIPLINARY MEETING

  • Team-based approach to evaluating all evidence in order to reach a consensus diagnosis16

REFERENCES

  1. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431-440. doi: 10.1164/rccm.201006-0894CI.
  2. King TE, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001;164(6):1025-1032. doi: 10.1164/ajrccm.164.6.2001056.
  3. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171(6):639-644. doi: 10.1164/rccm.200403-331OC.
  4. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824. doi: 10.1164/rccm.2009-040GL.
  5. van Manen MJG, Birring SS, Vancheri C, et al. Cough in idiopathic pulmonary fibrosis. By Respir Rev. 2016;25(141):278-286. doi: 10.1183/16000617.0090-2015.
  6. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157(1):199-203. doi: 10.1164/ajrccm.157.1.9704130.
  7. King TE, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164(7):1171-81. doi: 10.1164/ajrccm.164.7.2003140.
  8. Douglas W, Ryu JH, Schroeder DR, et al. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med. 2000; 161(4 Pt 1):1172-1178. doi: 10.1164/ajrccm.161.4.9907002.
  9. Cottin V, Cordier JF. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J. 2012;40(3):519-521. doi: 10.1183/09031936.00001612.
  10. Swigris JJ, Stewart AL, Gould MK, et al. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes. 2005;3:61. doi: 10.1186/1477-7525-3-61.
  11. Lee JS, McLaughlin S, Collard HR. Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2011;17(5):348-354. doi: 10.1097/MCP.0b013e328349721b.
  12. Olson A, KK Brown, Swigris JJ. Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibro-sis. Patient Related Outcome Measures. 2016;7:29-35. doi: 10.2147/PROM.S74857.
  13. Cordier JF, Cottin V. Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis. Eur Respir J. 2013;42(4):916-923. doi: 10.1183/09031936.00027913.
  14. Collard HR, Tino G, Noble PW, et al. Patient experiences with pulmonary fibrosis. Respir Med. 2007;101(6):1350-1354. doi: 10.1016/j.rmed.2006.10.002.
  15. Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med. 2011;184(7):842-847. doi: 10.1164/rccm.201104-0668OC.
  16. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.
  17. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511-522. doi: 10.1183/09031936.05.00035005.
  18. Garcia CK, Talbert JL. Pulmonary Fibrosis Predisposition Overview. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; January 21, 2005.
  19. Garcia-Sancho C, Buendía-Roldán I, Fernández-Plata MR, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med. 2011;105(12):1902-1907. doi: 10.1016/j.rmed.2011.08.022.
  20. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-968. doi: 10.1183/09031936.05.00035205.
  21. Pulmonary Fibrosis Foundation Patient Information Guide. Available at http://www.pulmonaryfibrosis.org/docs/default-source/patient-information-guides/2017-pff-patlent-information-guide.pdf?sfvrsn=0. Accessed July 12, 2017.
  22. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013,143(3):814-824. doi: 10.1378/chest.12-0741.

See also

Test your Knowledge
Test your knowledge

Take the test

Lung X-Ray Example
Rad Rounds Mobile App

Download the app

Interstitial lung disease in systemic sclerosis with a focus on chest CT

Media Library

See Media